Is MSI Testing Using NGS Data Accurate?
US FDA approves treatment for cancers with high microsatellite instability (MSI-H) highlight the importance of MSI testing in cancer treatment ; more and more companies adopting to use NGS data for MSI assessment, and the biggest benefit of NGS-based MS
SG MSL Team of ACT Genomics 2020-10-13
Ovarian Cancer Patient: Ms. Chang
While fighting ovarian cancer for 18 years, Ms. Chang underwent several rounds of chemotherapy and surgery. At her last check-up, her cancer was found to have metastasized. She was at the point of accepting her fate when her attending doctor recommended genomic profiling, which led to a treatment recommendation that had not previously been considered.
Squamous Cell Skin Cancer Patient: Ms. Chen
The family members of 87-year-old Ms. Chen were reluctant that she be made to endure another surgery when her cancer relapsed owing to her age and effects of previous surgeries. Genomic profiling was then explored with her doctor to identify if she might be a candidate of immunotherapy. Fortunately, she is.
Phase 3 THOR study: Results of erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer with selective fibroblast growth factor receptor alterations
Currently, immune checkpoint inhibitors (ICIs) are widely used as first-line therapy for patients with metastatic urothelial carcinoma who are ineligible for platinum-based therapy or who have failed first-line platinum-based chemotherapy. However, only 30% of patients receive subsequent anti-cancer treatments after discontinuing ICI. Several genomic studies of metastatic urothelial carcinoma have shown FGFR2/3 alterations in 20% of patients, and erdafitinib has demonstrated clinical benefit in patients with disease progression after platinum-based chemotherapy.
ORCHID Trial Shows Potential for Olaparib in Patients with Metastatic Renal Cell Carcinoma Carrying Mutations in BAP1 or Other DNA Repair Genes
In the interim analysis of the ORCHID study, metastatic renal cell carcinoma patients with BAP1 or other DNA repair gene mutations benefited from olaparib, which were presented at the 2023 Kidney Cancer Research Summit.
The First Treatment-switching by Monitoring Plasma ESR1 Mutations with circulating tumor DNA (ctDNA) Demonstrated Promising Clinical Benefit in the Phase III PADA-1 Study
Abstract: ASCO 2023 annual meeting updated with latest data from PADA-1 study, switching aromatase inhibitor (AI) to fulvestrant in case of rising ESR1 mutations by longitudinal ctDNA monitoring, showing progression-free survival1 (PFS1) and PFS2 significantly improved.
TALAPRO-2: Phase III study of talazoparib plus enzalutamide as first-line treatment for mCRPC patients harboring homologous recombination repair gene alterations
The TALAPRO-2 study demonstrated a statistically improvement of rPFS with talazoparib and enzalutamide combination in HRR gene-mutated mCRPC.
What are the benefits of genetic testing for cancer?
ACT Genomics received the 2021 Frost & Sullivan Best Practices Award in Asia-pacific Clinical Oncology Next-generation Sequencing Workflow Solutions Product Leadership.